CN105504051B - 狂犬病毒核蛋白单克隆抗体及其应用 - Google Patents
狂犬病毒核蛋白单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN105504051B CN105504051B CN201510955395.5A CN201510955395A CN105504051B CN 105504051 B CN105504051 B CN 105504051B CN 201510955395 A CN201510955395 A CN 201510955395A CN 105504051 B CN105504051 B CN 105504051B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- seq
- antibody
- amino acid
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 18
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 9
- 206010037742 Rabies Diseases 0.000 claims abstract description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 238000001514 detection method Methods 0.000 claims description 20
- 210000004408 hybridoma Anatomy 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 241000711798 Rabies lyssavirus Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000090 biomarker Substances 0.000 claims description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 206010053317 Hydrophobia Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 238000008157 ELISA kit Methods 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 238000011895 specific detection Methods 0.000 claims description 2
- 101710091977 Hydrophobin Proteins 0.000 abstract description 14
- 229960005486 vaccine Drugs 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 7
- 239000000427 antigen Substances 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 3
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 230000009610 hypersensitivity Effects 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 7
- 108010061100 Nucleoproteins Proteins 0.000 description 7
- 102000011931 Nucleoproteins Human genes 0.000 description 7
- 101900236200 Rabies virus Nucleoprotein Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229960003127 rabies vaccine Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229920006221 acetate fiber Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510955395.5A CN105504051B (zh) | 2015-12-17 | 2015-12-17 | 狂犬病毒核蛋白单克隆抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510955395.5A CN105504051B (zh) | 2015-12-17 | 2015-12-17 | 狂犬病毒核蛋白单克隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105504051A CN105504051A (zh) | 2016-04-20 |
CN105504051B true CN105504051B (zh) | 2019-08-30 |
Family
ID=55712399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510955395.5A Active CN105504051B (zh) | 2015-12-17 | 2015-12-17 | 狂犬病毒核蛋白单克隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105504051B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106802348A (zh) * | 2016-12-30 | 2017-06-06 | 广东华南联合疫苗开发院有限公司 | Sf弹状病毒N蛋白双抗夹心酶联免疫检测试剂盒及方法 |
CN111171145B (zh) * | 2020-01-21 | 2021-11-05 | 兰州生物制品研究所有限责任公司 | 一种抗狂犬病病毒单克隆抗体、制备方法及用途 |
CN114958774B (zh) * | 2022-05-08 | 2023-10-27 | 中国医学科学院医学生物学研究所 | 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101413948A (zh) * | 2008-11-13 | 2009-04-22 | 浙江大学 | 犬狂犬病病毒np-elisa抗体检测试剂盒 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX341147B (es) * | 2011-05-13 | 2016-08-09 | Ganymed Pharmaceuticals Ag | Anticuerpos para el tratamiento del cáncer que expresa cldn6. |
-
2015
- 2015-12-17 CN CN201510955395.5A patent/CN105504051B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101413948A (zh) * | 2008-11-13 | 2009-04-22 | 浙江大学 | 犬狂犬病病毒np-elisa抗体检测试剂盒 |
Non-Patent Citations (2)
Title |
---|
抗狂犬病毒核蛋白荧光标记抗体的制备和初步鉴定;严家新等;《中国人寿共患病杂志》;20001020;第16卷(第5期);第1.3-1.7、2.4-2.5、3节,第59页第1段 |
抗狂犬病毒糖蛋白及核蛋白单抗的研制及应用;徐葛林等;《中国生物制品学杂志》;19960215;第9卷(第1期);第23页第6节,第24页第3节,表2 |
Also Published As
Publication number | Publication date |
---|---|
CN105504051A (zh) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007074811A1 (ja) | A型インフルエンザウイルス強毒株の検出法 | |
CN103665155B (zh) | 一种抗流感病毒广谱中和性的中和分子1f2 | |
CN105504051B (zh) | 狂犬病毒核蛋白单克隆抗体及其应用 | |
JP2008196967A (ja) | インフルエンザウイルスh5亜型の免疫検出法 | |
Chattopadhyay et al. | Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application | |
Kobayashi et al. | Characterization and epitope mapping of monoclonal antibodies raised against rat hepatitis E virus capsid protein: An evaluation of their neutralizing activity in a cell culture system | |
CN106771181A (zh) | 一种禽流感h7n9血凝素ha抗原检测 elisa 试剂盒及检测方法 | |
CN110272488A (zh) | 猫杯状病毒单克隆抗体及其应用 | |
CN113604438B (zh) | 一种抗罗非鱼湖病毒的单克隆抗体及其细胞株和应用 | |
CN103254312B (zh) | 一种鼠源单克隆抗体及其制备方法和用途 | |
de Carvalho Nicacio et al. | Neutralizing human Fab fragments against measles virus recovered by phage display | |
CN116836270B (zh) | 一种抗蓝舌病毒vp7蛋白的单克隆抗体及制备方法与用途 | |
CN106119209B (zh) | 一种抗肠道病毒EV71 IgA单克隆抗体及应用 | |
EP2521735A2 (en) | Recombinant human bivalent diabody against rabies virus and uses thereof | |
CN106701687A (zh) | 一种杂交瘤细胞株及其产生的狂犬病毒磷蛋白单克隆抗体 | |
CN101591390B (zh) | 抗h5n1来源的禽流感病毒核蛋白np的单克隆抗体及其应用 | |
CN103665153B (zh) | 一种抗流感病毒广谱中和性的中和分子1e1 | |
Fayaz et al. | Development and characterization of mouse monoclonal antibodies to canine morbillivirus | |
Munasinghe et al. | Immuno-dominant dengue NS1 peptides as antigens for production of monoclonal antibodies | |
CN103214571A (zh) | 一种鼠源单克隆抗体及其制备方法和用途 | |
CN103374070B (zh) | 一种抗狂犬病毒的结合分子2f5 | |
CN107011435B (zh) | 抗丙型肝炎病毒的全人单克隆抗体8d6 | |
CN105814077A (zh) | 能够中和狂犬病毒的结合分子 | |
KR20190138610A (ko) | 무지개송어의 면역글로불린 m에 특이적인 단클론항체 및 이의 용도 | |
CN104892755B (zh) | 百日咳prn 蛋白单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200804 Address after: D1117, Xinhua International Plaza, 89 Dayangfang Road, Shilihe, Chaoyang District, Beijing 100122 Patentee after: BEIJING PAIDICHANG TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 101111 Beijing City, Daxing District branch of Beijing economic and Technological Development Zone, 14 Street No. 99 Building No. 18 2-201B Patentee before: ABMAX BIOPHARMACEUTICALS |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211210 Address after: 101111 2-201b, building 18, No. 99, Kechuang 14th Street, economic and Technological Development Zone, Daxing District, Beijing Patentee after: ABMAX BIOPHARMACEUTICALS Address before: D1117, Xinhua International Plaza, No. 89, Dayangfang Road, Shilihe, Chaoyang District, Beijing 100122 Patentee before: BEIJING PAIDICHANG TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231027 Address after: No. 18-2-201, No. 99, Kechuang 14th Street, Daxing District Economic and Technological Development Zone, Beijing, 101111 Patentee after: ABMAX BIOTECHNOLOGY Co.,Ltd. Address before: 101111 2-201b, building 18, No. 99, Kechuang 14th Street, economic and Technological Development Zone, Daxing District, Beijing Patentee before: ABMAX BIOPHARMACEUTICALS |